FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Archidply IPO and Bafna Pharmaceuticals IPO.
Archidply IPO is a Mainline Fixed Price Issue IPO proposed to list at BSE, NSE while Bafna Pharmaceuticals IPO is a Mainline Fixed Price Issue proposed to list at BSE.
Archidply IPO | Bafna Pharmaceuticals IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Fixed Price Issue |
Listing At | BSE, NSE | BSE |
Lead Managers | Motilal Oswal Investment Advisors Limited | Keynote Financial Services Ltd Ashika Capital Ltd |
Registrar | Kfin Technologies Limited | Cameo Corporate Services Limited |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | ||
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Archidply IPO is up to ₹48.96 Cr whereas the issue size of the Bafna Pharmaceuticals IPO is up to ₹25.60 Cr. The final issue price of Archidply IPO is ₹74.00 per share and of Bafna Pharmaceuticals IPO is ₹40.00 per share.
Archidply IPO | Bafna Pharmaceuticals IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹70.00 per share | |
Issue Price (Upper) | ₹80.00 per share | |
Issue Price (Final) | ₹74.00 per share | ₹40.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 75 shares | |
Fresh Issue Size | ||
Fresh Issue Size (Amount) | ||
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 66,15,720 shares | 64,00,000 shares |
Issue Size Total (Amount) | up to ₹48.96 Cr | up to ₹25.60 Cr |
Archidply IPO opens on Jun 11, 2007, while Bafna Pharmaceuticals IPO opens on May 27, 2008. The closing date of Archidply IPO and Bafna Pharmaceuticals IPO is Jun 17, 2008, and May 30, 2008, respectively.
Archidply IPO | Bafna Pharmaceuticals IPO | |
---|---|---|
Anchor Bid Date | ||
Issue Open | Jun 11, 2007 | May 27, 2008 |
Issue Close | Jun 17, 2008 | May 30, 2008 |
Basis Of Allotment (Tentative) | ||
Initiation of Refunds (Tentative) | ||
Credit of Share (Tentative) | ||
Listing date (Tentative) | ||
Anchor Lockin End date 1 | ||
Anchor Lockin End date 2 |
Archidply IPO P/E ratio is , as compared to Bafna Pharmaceuticals IPO P/E ratio of .
Archidply IPO | Bafna Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 97.68% | 71.07% | ||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 68.31% | 42.6% | ||||||||||||||||||||||||||||||||||||
P/E Ratio | ||||||||||||||||||||||||||||||||||||||
Market Cap | ||||||||||||||||||||||||||||||||||||||
ROE | ||||||||||||||||||||||||||||||||||||||
ROCE | ||||||||||||||||||||||||||||||||||||||
Debt/Equity | ||||||||||||||||||||||||||||||||||||||
EPS | ||||||||||||||||||||||||||||||||||||||
RoNW | 21.87%% | 10.65%% |
In the Archidply IPO retail investors (RII) are offered while in Bafna Pharmaceuticals IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Archidply IPO and in Bafna Pharmaceuticals IPO.
Archidply IPO | Bafna Pharmaceuticals IPO | |
---|---|---|
Anchor Investor Reserveration | ||
Market Maker Reserveration | ||
QIB | ||
NII | ||
RII | ||
Employee | ||
Others | ||
Total |
Archidply IPO subscribed 1.52x in total, whereas Bafna Pharmaceuticals IPO subscribed .
Archidply IPO | Bafna Pharmaceuticals IPO | |
---|---|---|
QIB (times) | 0.20x | |
NII (times) | 2.36x | |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 3.04x | |
Employee (times) | ||
Other (times) | ||
Total (times) | 1.52x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|